bluebird bio Inc (NASDAQ:BLUE) shares shed more than 11% on Friday after the Massachusetts-based biotech company developing gene therapies for severe...…
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline…
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, April 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
NEW YORK, April 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…
NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action…
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the bluebird…
NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform pessimistic expectations regarding the launch of its Lyfgenia...…
bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform pessimistic expectations regarding the launch of its Lyfgenia...…
The answer hardly inspires confidence.…
Biotech company bluebird bio Inc (NASDAQ:BLUE) has priced its underwritten public offering, making 83,333,333 shares of common stock available at…
Der Ausverkauf bei der Aktie des amerikanischen Gentherapie-Spezialisten Bluebird Bio setzt sich zur Wochenmitte fort. Mit einem Minus von gut…
Der Ausverkauf bei der Aktie des amerikanischen Gentherapie-Spezialisten Bluebird Bio setzt sich zur Wochenmitte fort. Mit einem Minus von gut…
bluebird bio Inc (NASDAQ:BLUE) shares took off on Thursday after the biotechnology company provided positive patient start guidance for the…
bluebird bio Inc (NASDAQ:BLUE) may have secured FDA approval for its sickle cell disease cell therapy, Lyfgenia, but market reaction has been…
The Global Hemoglobinopathies Market Size was valued at USD 7.85 Billion in 2022 and the Worldwide Hemoglobinopathies Market Size is…
bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved…
Colvin, Richard A. - Vorstand - Tag der Transaktion: 2023-01-11...…
Obenshain, Andrew - Vorstand - Tag der Transaktion: 2023-01-11...…
Leschly, Nick - Aufsichtsrat - Tag der Transaktion: 2023-01-11...…
Colvin, Richard A. - Vorstand - Tag der Transaktion: 2022-11-04...…
Obenshain, Andrew - Vorstand - Tag der Transaktion: 2022-11-04...…